Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 3/2015

01-03-2015 | Nephrology - Original Paper

The protective effect of MCP-1 -2518 A>G promoter polymorphism in Turkish chronic renal failure patients requiring long-term hemodialysis

Authors: Binnur Bagci, Gokhan Bagci, Ferhan Candan, Ozturk Ozdemir, Ilhan Sezgin

Published in: International Urology and Nephrology | Issue 3/2015

Login to get access

Abstract

Objective

Monocyte chemoattractant protein-1 (MCP-1) plays a major role in the pathogenesis and progression of different types of human renal disease. Therefore, in this study, we aimed to investigate the effect of MCP-1 gene -2518 A>G promoter polymorphism in chronic renal failure (CRF) patients requiring long-term hemodialysis.

Methods

The study population consisted of 201 adult CRF patients requiring long-term hemodialysis and 194 healthy controls. The polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) technique was used for genotyping of MCP-1 -2518 A>G polymorphism in the CRF patients and healthy controls.

Results

There were statistically significant differences in terms of genotypic (χ 2 = 12.69, p = 0.02) and allelic (χ 2 = 5.72, p = 0.02) frequencies of MCP-1 -2518 A>G between CRF patients and control subjects. According to our results, in the patient group MCP-1 -2518 AA genotype frequency was significantly higher than that of control group. On the other hand, heterozygous AG genotype frequency in the control group was significantly higher than that of the study group. Three different main disease subgroups of CRF (hypertension, diabetes mellitus, and atherosclerosis) patients were also evaluated, and significant associations were found between hypertension (genotype: χ 2 = 9.28, p = 0.01; allele: χ 2 = 6.00, p = 0.01), atherosclerosis (genotype: χ 2 = 5.37, p = 0.02; allele: χ 2 = 4.13, p = 0.04), and distributions of MCP-1 -2518 A>G genotypes and alleles. However, no significant association was found between diabetes mellitus and distributions of MCP-1 -2518 A>G genotype and allele frequencies (genotype: χ 2 = 2.37, p = 0.3; allele: χ 2 = 1.88, p = 0.17).

Conclusion

Current data show that MCP-1 -2518 AA genotype may cause susceptibility to CRF, while G allele may have a protective effect against development of CRF. In addition, MCP-1 -2518 AA genotype seems to associate with CRF originated from hypertension and atherosclerosis in our study population.
Literature
1.
Segerer S, Nelson PJ (2005) Chemokines in renal diseases. Sci World J 29:835–844CrossRef
2.
Sean Eardley K, Cockwell P (2005) Macrophages and progressive tubulointerstitial disease. Kidney Int 68:437–455CrossRefPubMed
3.
Wada T, Yokoyama H, Kobayashi K (2000) Chemokines: new target molecules in renal diseases. Clin Exp Nephrol 4:273–280CrossRef
4.
Eis V, Vielhauer V, Anders HJ (2004) Targeting the chemokine network in renal inflammation. Arch Immunol Ther Exp (Warsz) 52:164–172
5.
Segerer S, Nelson PJ, Schlöndorff D (2000) Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11:152–176PubMed
6.
Furuichi K, Wada T, Kaneko S (2011) Cytokines and chemokines as therapeutic targets for ischemic kidney injury. Inflamm Regen 31:365–369CrossRef
7.
8.
Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, Howie AJ, Adu D, Cockwell P (2006) The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 69:1189–1197CrossRefPubMed
9.
Mori H, Kaneko Y, Narita I, Goto S, Saito N, Kondo D, Sato F, Ajiro J, Saga D, Ogawa A, Sakatsume M, Ueno M, Tabei K, Gejyo F (2005) Monocyte chemoattractant protein-1 A-2518G gene polymorphism and renal survival of Japanese patients with immunoglobulin A nephropathy. Clin Exp Nephrol 9:297–303CrossRefPubMed
10.
Viedt C, Dechend R, Fei J, Hänsch GM, Kreuzer J, Orth SR (2002) MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kB and activating protein-1. J Am Soc Nephrol 13:1534–1547CrossRefPubMed
11.
Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kübler W, Kreuzer J (2002) Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kB and activator protein-1. Arterioscler Thromb Vasc Biol 22:914–920CrossRefPubMed
12.
Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR (1999) Monocyte chemoattractant protein 1–dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Faslpr mice. J Exp Med 190:1813–1824CrossRefPubMedCentralPubMed
13.
Bird JE, Giancarli MR, Kurihara T, Kowala MC, Valentine MT, Gitlitz PH, Pandya DG, French MH, Durham SK (2000) Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int 57:129–136CrossRefPubMed
14.
Sezgin I, Koksal B, Bagci G, Kurtulgan HK, Ozdemir O (2011) CCR2 polymorphism in chronic renal failure patients requiring long-term hemodialysis. Intern Med 50:2457–2461CrossRefPubMed
15.
Rovin BH, Lu L, Saxena R (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259:344–348CrossRefPubMed
16.
Jibiki T, Terai M, Shima M, Ogawa A, Hamada H, Kanazawa M, Yamamoto S, Oana S, Kohno Y (2001) Monocyte chemoattractant protein-1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein-1 in Japanese patients with Kawasaki disease. Arthritis Rheum 44:2211–2212CrossRefPubMed
17.
Kim MJ, Tam FW (2011) Urinary monocyte chemoattractant protein-1 in renal disease. Clin Chim Acta 412:2022–2030CrossRefPubMed
18.
Tesch GH, Schwarting A, Kinoshita K, Lan HY, Rollins BJ, Kelley VR (1999) Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 103:73–80CrossRefPubMedCentralPubMed
19.
Ozdemir O, Kayatas M, Cetinkaya S, Yildirim ME, Silan F, Kurtulgan HK, Koksal B, Urfali M, Candan F (2014) Bcıı-RFLP profiles for serum amiloid A1 and mutated MEFV gene prevalence in chronic renal failure patients requiring long-term hemodialysis. Ren Fail. doi:10.​3109/​0886022X.​2014.​982954
20.
Sanders SK, Crean SM, Boxer PA, Kellner D, LaRosa GJ, Hunt SW (2000) Functional differences between monocyte chemotactic protein-1 receptor A and monocyte chemotactic protein-1 receptor B expressed in a Jurkat T cell. J Immunol 165:4877–4883CrossRefPubMed
21.
Cho ML, Yoon BY, Ju JH, Jung YO, Jhun JY, Park MK, Cho CS, Kim HY (2007) Expression of CCR2A, an isoform of MCP-1 receptor, is increased by MCP-1, CD40 ligand and TGF-beta in fibroblast like synoviocytes of patients with RA. Exp Mol Med 39:499–507CrossRefPubMed
22.
Steinmetz OM, Panzer U, Harendza S, Mertens PR, Ostendorf T, Floege J, Helmchen U, Stahl RA (2004) No association of the –2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy. Nephrol Dial Transplant 19:596–601CrossRefPubMed
23.
Malafronte P, Vieira JM Jr, Pereira AC, Krieger JE, Barros RT, Woronik V (2010) Association of the MCP-1 -2518 A/G polymorphism and no association of its receptor CCR2 -64 V/I polymorphism with lupus nephritis. J Rheumatol 37:776–782CrossRefPubMed
24.
Buraczynska M, Skublewska AB, Buraczynska K, Ksiazek A (2008) Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients. Cytokine 44:361–365CrossRefPubMed
25.
Hassan AM, Nagy H, Mohamed WS (2010) Circulating MCP-1 level and 2518 gene polymorphism as a marker of nephropathy development in Egyptian patients. Egypt J Med Hum Genet 11:159–166CrossRef
26.
Krüger B, Schröppel B, Ashkan R, Marder B, Zülke C, Murphy B, Krämer BK, Fischereder M (2002) A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 13:2585–2589CrossRefPubMed
27.
Lehmann I, Fischereder M, Böhmig GA, Regele H, Exner M, Raith M, Weiss N, Segerer S (2008) The source matters: no impact of the CCL2/MCP-1-1-2518G polymorphism of the donor on renal allograft outcome during the first year after transplantation. Transplant Proc 40:3359–3361CrossRefPubMed
28.
Tesch GH (2008) MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294:F697–F701CrossRefPubMed
29.
Joo KW, Hwang YH, Kim JH, Oh KH, Kim H, Shin HD, Chung WK, Yang J, Park KS, Ahn C (2007) MCP-1 and RANTES Polymorphisms in Korean Diabetic End-Stage Renal Disease. J Korean Med Sci 22:611–615CrossRefPubMedCentralPubMed
30.
Moon JY, Jeong L, Lee S, Jeong K, Lee T, Ihm CG, Suh J, Kim J, Jung YY, Chung JH (2007) Association of polymorphisms in monocyte chemoattractant protein-1 promoter with diabetic kidney failure in Korean patients with type 2 diabetes mellitus. J Korean Med Sci 22:810–814CrossRefPubMedCentralPubMed
31.
Kouyama K, Miyake K, Zenibayashi M, Hirota Y, Teranishi T, Tamori Y, Kanda H, Sakaguchi K, Ohara T, Kasuga M (2008) Association of serum MCP-1 concentration and MCP-1 polymorphism with insulin resistance in Japanese individuals with obese type 2 diabetes. Kobe J Med Sci 53(6):345–354PubMed
32.
Eriksson EE (2004) Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol 15(5):553–558CrossRefPubMed
33.
Bağcı G, Çinçin ZB, Daşdemir S, Özdemircan A, Karaali ZE, Çakmakoğlu B (2011) The effects of MCP-1 A-2518G and CCR2 G190A gene polymorphism on development of diabetic coronary artery disease. Deneysel Tıp Araştırma Enstitüsü Dergisi 1(2):9–13
34.
Kaur R, Matharoo K, Arora P, Bhanwer AJ (2013) Association of -2518 A > G promoter polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene with type 2 diabetes and coronary artery disease. Genet Test Mol Biomark 17:750–755CrossRef
35.
Tabara Y, Kohara K, Yamamoto Y, Igase M, Nakura J, Kondo I, Miki T (2003) Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. Hypertens Res 26:677–683CrossRefPubMed
36.
Yuasa S, Maruyama T, Yamamoto Y, Hirose H, Kawai T, Matsunaga-Irie S, Itoh H (2009) MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res Clin Pract 86:193–198CrossRefPubMed
37.
Alexander RW (1995) Hypertension and pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response. Hypertension 25:155–161CrossRefPubMed
38.
Capers Q, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, Howard AB, Taylor WR (1997) Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 30:1397–1402CrossRefPubMed
39.
Penz P, Bucova M, Lietava J, Blazicek P, Paulovicova E, Mrazek F, Bernadic M, Buckingham TA, Petrek M (2010) MCP-1 -2518 A/G gene polymorphism is associated with blood pressure in ischemic heart disease asymptomatic subjects. Bratisl Lek Listy 111:420–425PubMed
Metadata
Title
The protective effect of MCP-1 -2518 A>G promoter polymorphism in Turkish chronic renal failure patients requiring long-term hemodialysis
Authors
Binnur Bagci
Gokhan Bagci
Ferhan Candan
Ozturk Ozdemir
Ilhan Sezgin
Publication date
01-03-2015
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2015
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-015-0922-3

Other articles of this Issue 3/2015

International Urology and Nephrology 3/2015 Go to the issue

Nephrology – Original Paper

Peritoneal dialysis catheter placement in the right lower quadrant is associated with a lower risk of catheter tip migration: a retrospective single-center study

Urology - Original Paper

The possible role of percutaneous tibial nerve stimulation using adhesive skin surface electrodes in patients with neurogenic detrusor overactivity secondary to spinal cord injury

Urology - Original Paper

Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study

Urology – Original Paper

Does the presence of hydronephrosis have effects on micropercutaneous nephrolithotomy?

Nephrology – Original Paper

Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis

Nephrology - Original Paper

Clinicopathological and outcome analysis of adult lupus nephritis patients in China
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits